Medline Inc. (MDLN)

Key figures

The last twelve months reported, with the latest price and balance sheet.

Market value

$27.9B

Cash

$2.3B

Debt

$12.6B

Debt to equity

1.09

Financial statements

Revenue, profit and cash flow by fiscal year, each year linked to its annual report.

By quarter

What the company said with its results

From the second quarter 2026 results, filed 5 August 2026.

• Second quarter net sales up 11.6%. Net sales reached $7.7 billion, with Organic Sales up 11.5%, driven mainly by existing customer growth and implementation of 2025 new customer signings.
• Net income fell 58.3% on Tracy fire. Net income was $139 million against $333 million, mainly from $336 million of fire losses before insurance recoveries, plus higher operating expenses and cost of goods sold.
• Adjusted EBITDA up 13.4%. Adjusted EBITDA reached $1,060 million, helped by higher net sales and IEEPA tariff refund benefits, partly offset by higher operating expenses and cost of goods sold.
• First-half net sales up 11.1%. Six-month net sales rose 11.1% to $15.0 billion, with Organic Sales up 10.8%; six-month net income fell 42.3% to $378 million.
• Quarterly and six-month per-share results. Diluted EPS was $0.07 and Adjusted Diluted EPS was $0.50 for the quarter; the six-month figures were $0.23 and $0.83.
• Medline Brand sales up 6.6%. Medline Brand net sales rose 6.6% to $3.54 billion; its Adjusted EBITDA rose 19.9% to $1,067 million, a 30.1% margin against 26.8%.
• IEEPA refund entries sit in Medline Brand. The company recorded all IEEPA tariff refund amounts within the Medline Brand segment, and they were included in its net income and Adjusted EBITDA.
• Supply Chain Solutions sales up 16.3%. Supply Chain Solutions net sales rose 16.3% to $4.15 billion; its Adjusted EBITDA rose 1.5% to $204 million, a 4.9% margin against 5.6%.
• Corporate costs rose 35.3%. Corporate & Other expense was $211 million against $156 million, covering centralized finance, IT, legal, HR and internal audit functions.
• Over 65% of annual signing goal. Management said the company secured over 65% of its annual goal for total new customer signings in the first half of 2026.
• IEEPA repayments reduced net sales. Net sales include $89 million of accrued customer repayments tied to IEEPA tariff refunds, which reduced net sales in the quarter and six months.
• Existing and new customer demand cited. Management tied the raised Organic Sales guidance to existing and new customer demand.
• Gross margin rose to 28.8%. Gross margin was 28.8% against 27.7% a year earlier, with cost of goods sold up 9.8% to $5.47 billion.
• Tariff refunds lowered cost of goods sold. Tariff refunds of $332 million reduced cost of goods sold, partly offset by $89 million of repayments that reduced net sales.

Revenue by segment

As the company reports it in the segment note of its annual report.

By business, FY2025

By region, FY2025

Company events

The newest 8-K filings of 9 held.

Every filing

The newest filings with the SEC of 40 held.

Insider trades

Form 4 trades by officers, directors and 10% owners, last 12 months.

Planned insider sales

Form 144 notices, filed when the sell order goes to the broker.

Large holders

Schedule 13D and 13G filings by holders of more than 5% of the voting shares.

Short interest

Shares sold short and not yet bought back, on each FINRA settlement date.

Funds that hold it

From each fund's latest Form 13F.

487 funds held it at 30 Jun 2026: 314 added and 67 trimmed in the quarter. The largest:

Peers

Companies in the same industry.

• Stryker Corp. (SYK): revenue $25.8B, market value $116.7B
• 3M Co. (MMM): revenue $25.2B, market value $89.3B
• Boston Scientific Corp. (BSX): revenue $21.0B, market value $61.4B
• Becton Dickinson & Co. (BDX): revenue $20.8B, market value $53.2B
• Resmed Inc. (RMD): revenue $5.7B, market value $36.1B
• Dexcom Inc. (DXCM): revenue $5.0B, market value $29.7B
• West Pharmaceutical Services Inc. (WST): revenue $3.3B, market value $28.4B
• Solventum Corp. (SOLV): revenue $8.3B, market value $13.9B
• Baxter International Inc. (BAX): revenue $11.5B, market value $13.2B
• Penumbra Inc. (PEN): revenue $1.5B, market value $12.5B

What the company does

Medline is a provider of medical-surgical ("med-surg") products and supply chain services, which the company describes as the largest on total net sales of med-surg products. It was founded in 1966 and sells to hospitals, surgery centers, physician offices and post-acute facilities. Through two segments it offers approximately 335,000 med-surg products, including surgical and procedural kits, gloves and protective apparel, urological and incontinence care, wound care, and consumable lab and diagnostics products. It employs over 45,000 people worldwide.

How the business is organised

Medline reports two segments, Medline Brand and Supply Chain Solutions. Medline Brand made up 48.3% of total net sales and Supply Chain Solutions made up 51.7%. Both segments are supported by the Prime Vendor model, the distribution network and the commercial team.

As of 31 December 2025 it offered approximately 190,000 products. Supply Chain Solutions offered approximately 145,000 products from over 1,300 third-party suppliers. It also sells services such as consulting, outsourced warehouse and technology management, put-away-ready packaging, third-party logistics, inventory rationalization and route planning.

What it sells

Medline Brand products fall into three categories:

- Front Line Care: wound care, exam gloves, skin care and incontinence products, environment cleaning supplies, textiles, hand sanitizer, durable medical equipment, patient plastics, and decolonization and infection control products. - Surgical Solutions: surgical procedure trays, drapes and gowns, personal protective equipment, sterile wraps, surgical instruments, surgeon's gloves, procedure kits and orthopedic implants. - Laboratory and Diagnostics: point of care testing, analyzers and instrumentation, lab and diagnostic consumables, vital signs monitors, and anatomic pathology and phlebotomy products.

The filing names Medline, Curad, Microtek, Hudson and Proxima among its notable brands. The company holds more than 2,300 granted patents and more than 450 FDA 510(k) clearances, and it launched more than 250 new products over the last three years.

The Prime Vendor model

A Prime Vendor relationship is a multi-year distribution agreement under which a customer agrees to use Medline for the vast majority of its med-surg product needs. These agreements are typically structured with five-year terms. Medline had over 1,600 Prime Vendor relationships as of 31 December 2025, and the company reports a greater than 98% average Prime Vendor retention rate over the past five years.

As of that date, Prime Vendor agreements had an approximate average mix of 65% Supply Chain Solutions and 35% Medline Brand. The company says Medline Brand products carry lower prices than third-party alternatives and that it has historically earned higher margins when customers switch from third-party national brands to like-for-like Medline Brand products. It also says such a switch typically lowers net sales if volume stays constant.

How it makes and sources products

Medline manufactures approximately one-third of its Medline Brand products, mostly Class I and II medical devices, in 30 manufacturing facilities, 24 of them in North America. For most of the rest it works with more than 600 global partners across approximately 40 countries. No single sourcing partner accounted for more than 5% of total spend. The company uses ethylene oxide to sterilize certain products and has two primary sterilization facilities for it.

Distribution and sales force

The distribution network has 70 distribution centers, warehouses, cross-docks and transship facilities, 45 of them in the United States. It is set up to provide next-day delivery to 95% of the U.S. customer base. The company uses artificial intelligence and robotics in over 26 million square feet of U.S. warehouse space and runs more than 2,100 MedTrans trucks of its own. As of 31 December 2025 it had approximately 25% in incremental capacity across the platform.

A U.S. commercial team of approximately 4,000 people includes account managers, product specialists, clinical resources, customer service representatives, supply chain specialists and Prime Vendor analysts.

Competitors, regulators and people

Medline competes with other med-surg manufacturers, many of which depend on third-party distributors. It also competes with distributors such as McKesson, Cardinal Health, Owens & Minor and Henry Schein for Prime Vendor agreements. No international market represents more than 3% of net sales.

The business is regulated by the FDA, the Centers for Medicare & Medicaid Services, the Federal Trade Commission and other agencies. None of its products is currently approved under a premarket approval application.

Of its employees, over 26,000 are in the United States, and none of them are unionized. The largest non-U.S. employee populations are in Mexico, Dominican Republic, India, Canada, Slovakia, France, China, Japan, Germany and Australia.

*From Medline's annual report on Form 10-K for the year ended 31 December 2025. [The filing](https://www.sec.gov/Archives/edgar/data/2046386/000204638626000009/mdln-20251231.htm)*

From the company's 10-K.